Marizyme Inc Overview
Pro stress-test →Marizyme is a global medical technology company dedicated to transforming cardiac care by developing first-in-class vascular conduit solutions for coronary artery bypass graft (CABG) surgery. The company's flagship product, DuraGraft, is the first and only FDA-cleared vascular conduit solution that maintains the structural and functional integrity of saphenous vein grafts.
Strategic Profile
Pro stress-test →The company's core mission is to safeguard patient outcomes through the maintenance of vascular integrity, utilizing a proprietary platform designed to neutralize oxidative damage—a critical driver of vein graft ischemic reperfusion injury. In March 2025, Marizyme entered a non-binding Memorandum of Understanding with Qualigen Therapeutics to be acquired, following a co-marketing agreement established in 2024.
Competitive Landscape
Pro stress-test →Marizyme competes in the specialized cardiac medical device space, particularly in CABG graft solutions. Direct competitors include Cue Biopharma and INmune Bio. The company is differentiated by DuraGraft's FDA clearance and first-mover status in vascular integrity maintenance, though the ultra-small scale and acquisition pending limit competitive positioning.
Industry Context
Marizyme Inc operates in Cardiac vascular graft medical devices.
Key facts
Founded: 2007 · Headquarters: Jupiter, FL · Employees: 11 · Revenue: $183K · Market cap: $39.5K